HOWL
Werewolf Therapeutics Inc.
$1.31
-$0.09(-6.43%)
52
Overall
60
Value
45
Tech
--
Quality
Market Cap
$74.08M
Volume
1.23M
52W Range
$0.60 - $2.52
Target Price
$6.83
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | -- | $834.0K | $1.6M | $398.0K | ||
| Total Revenue | -- | $16.4M | $1.6M | $1.9M | ||
| GROSS PROFIT | ||||||
| Gross Profit | -- | $834.0K | $1.6M | $398.0K | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $50.1M | $72.5M | $60.4M | $75.5M | ||
| Research & Development | $35.3M | $53.8M | $41.8M | $56.4M | ||
| Research Expense | $35.3M | $53.8M | $41.8M | $56.4M | ||
| Selling, General & Administrative | $14.8M | $18.7M | $18.7M | $19.0M | ||
| General & Administrative Expenses | $14.8M | $18.7M | $18.7M | $19.0M | ||
| Salaries & Wages | -- | -- | $8.0M | $8.8M | ||
| Depreciation & Amortization | $200.0K | $1.1M | -- | -- | ||
| Depreciation & Amortization | $200.0K | $1.1M | -- | -- | ||
| Other Operating Expenses | $2.1M | $2.8M | $2.4M | $2.8M | ||
| OPERATING INCOME | ||||||
| Operating income | $-50.1M | $-56.1M | $-40.5M | $-73.6M | ||
| EBITDA | $-49.2M | $-51.1M | $-34.0M | $-64.5M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | -- | -- | $3.1M | $3.3M | ||
| Intinc | -- | $1.9M | $7.4M | $6.7M | ||
| Net Non-Operating Interest Income/Expense | -- | $-1.9M | $7.4M | $6.7M | ||
| Gain on Sale of Securities | $104.0K | $1.9M | -- | -- | ||
| Other Income/Expense | $-104.0K | $338.0K | $-18.8M | $-3.0M | ||
| Other Special Charges | -- | $16.7M | $18.8M | $3.0M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-50.0M | $-53.8M | $-37.4M | $-67.2M | ||
| Pre-Tax Income | $-50.0M | $-53.8M | $-34.3M | $-70.5M | ||
| NET INCOME | ||||||
| Net Income | $-50.0M | $-53.8M | $-37.4M | $-70.5M | ||
| Net Income (Continuing Operations) | $-50.0M | $-53.8M | $-37.4M | $-70.5M | ||
| Net Income (Discontinued Operations) | $-50.0M | $-53.8M | $-37.4M | $-70.5M | ||
| Net Income (Common Stockholders) | $-201.9M | $-53.8M | $-37.4M | $-70.5M | ||
| Normalized Income | $-39.5M | -- | -- | $-65.2M | ||
| TOTALS | ||||||
| Total Expenses | $50.1M | $72.5M | $60.4M | $75.5M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $18.5M | $28.9M | $35.6M | $43.3M | ||
| Average Shares Outstanding (Diluted) | $18.5M | $28.9M | $35.6M | $43.9M | ||
| Shares Outstanding | $27.7M | $35.3M | $42.7M | $44.8M | ||
| Basic EPS | $-10.94 | $-1.86 | $-1.05 | $-1.63 | ||
| Basic EPS (Continuing Operations) | $-10.94 | $-1.86 | $-1.05 | $-1.63 | ||
| Diluted EPS | $-10.94 | $-1.86 | $-1.05 | $-1.63 | ||
| Diluted EPS (Continuing Operations) | $-10.94 | $-1.86 | $-1.05 | $-1.63 | ||
| OTHER METRICS | ||||||
| Accretion On Preferred Stock | $151.9M | -- | -- | -- | ||
| Other Gand A | $14.8M | $18.7M | $18.7M | $19.0M | ||
| Otherunder Preferred Stock Dividend | $151.9M | -- | -- | -- | ||
| Preferred Stock Dividends | $151.9M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | HOWL | $1.31 | -6.4% | 1.23M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Werewolf Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW